Parallax Volatility Advisers, L.P. Viridian Therapeutics, Inc.\De Transaction History
Parallax Volatility Advisers, L.P.
- $53.5 Billion
- Q3 2024
A detailed history of Parallax Volatility Advisers, L.P. transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Parallax Volatility Advisers, L.P. holds 19,500 shares of VRDN stock, worth $388,635. This represents 0.0% of its overall portfolio holdings.
Number of Shares
19,500Holding current value
$388,635% of portfolio
0.0%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding VRDN
# of Institutions
182Shares Held
76.9MCall Options Held
581KPut Options Held
439K-
Black Rock Inc. New York, NY4.77MShares$95.1 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.42MShares$88.1 Million0.0% of portfolio
-
Vr Adviser, LLC New York, NY3.88MShares$77.4 Million9.15% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.75MShares$74.8 Million3.15% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA3.45MShares$68.7 Million12.74% of portfolio
About Viridian Therapeutics, Inc.\DE
- Ticker VRDN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,888,900
- Market Cap $795M
- Description
- Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...